The Acton, Massachusetts-based automated insulin delivery system maker also appointed Manoj Raghunandanan as chief growth officer.
In his expanded role, Benjamin now leads Insulet’s end-to-end growth and innovation engine. He sets the strategy and guides execution across new products, new markets and commercial expansion. In the position, he oversees strategy and business development, the office of the chief technology officer, R&D and the newly created growth organization, led by Raghunandanan.
Benjamin previously served as EVP of innovation and strategy, became Insulet’s chief product & consumer experience officer (CPXO) during a handful of executive changes in 2023. Insulet — one of the largest diabetes tech companies in the world — has made a handful of recent changes, including one at the top with the appointment of Ashley McEvoy as CEO in April.
“Eric has been a driving force in Insulet’s success,” said McEvoy, Insulet president and CEO. “He combines vision, execution, and a mission-first mindset that sets him apart – spotting opportunities in evolving markets, setting bold strategies, and building high-performing teams that deliver results. I look forward to partnering even more closely with him as we accelerate Insulet’s next chapter of growth and impact.”
Read more about Insulet and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.
Benjamin joined Insulet in 2015 and, in a number of progressive leadership roles, strengthened the company’s supply chain resilience, launched the Omnipod Dash and Omnipod 5 systems, expanded Insulet’s reach into the type 2 diabetes market, and digitized the customer experience to improve customer engagement and satisfaction.
Most recently, as EVP and CPXO, he directed global product strategy, customer experience, commercial execution and innovation.
“I’m honored to step into this role at such an important moment for Insulet and exciting time in the advancement of diabetes care,” said Benjamin. “We have an extraordinary opportunity to continue advancing life-changing technology and broaden global access to improve the lives of people with diabetes.”
More on Raghunandanan as Insulet expands leadership team
As Benjamin’s remit expands, Insulet is growing its leadership group with the appointment of Raghunandanan.
Raghunandanan has more than 20 years of global consumer health experience at Kenvue, the J&J Consumer Health spinoff. Most recently, he served as GM of the company’s Northern European business and sat on Kenvue’s executive committee for five years.
He also held leadership roles in the U.S., Europe and Asia, building high-performing teams, driving commercial excellence and scaling global brands.
In his new role, Raghunandanan will lead the newly formed Growth organization. This includes developing global strategy, overseeing demand generation, accelerating commercial capabilities, and stewarding the global brand and customer experience to accelerate the company’s next chapter of global growth.
“The addition of Manoj’s deep global growth expertise further enhances our leadership and positions us to seize new opportunities ahead,” McEvoy said.
